Farr Miller & Washington’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$1.06M Buy
9,814
+43
+0.4% +$4.91K 0.07% 97
2021
Q2
$1.1M Hold
9,771
0.07% 95
2021
Q1
$1.06M Buy
9,771
+22
+0.2% +$2.35K 0.07% 93
2020
Q4
$1.04M Buy
9,749
+400
+4% +$38.4K 0.08% 91
2020
Q3
$819K Buy
9,349
+22
+0.2% +$2.07K 0.07% 92
2020
Q2
$916K Buy
9,327
+12
+0.1% +$1.06K 0.07% 83
2020
Q1
$710K Buy
9,315
+50
+0.5% +$4.26K 0.07% 82
2019
Q4
$820K Hold
9,265
0.06% 87
2019
Q3
$702K Buy
9,265
+200
+2% +$13.7K 0.06% 90
2019
Q2
$659K Hold
9,065
0.05% 86
2019
Q1
$731K Sell
9,065
-73
-0.8% -$5.97K 0.06% 77
2018
Q4
$842K Sell
9,138
-662
-7% -$58.2K 0.08% 71
2018
Q3
$927K Sell
9,800
-200
-2% -$19K 0.08% 69
2018
Q2
$926K Sell
10,000
-155
-2% -$15.1K 0.08% 68
2018
Q1
$961K Sell
10,155
-100
-1% -$11K 0.09% 71
2017
Q4
$992K Hold
10,255
0.09% 68
2017
Q3
$911K Sell
10,255
-1,083
-10% -$82.4K 0.09% 69
2017
Q2
$822K Buy
11,338
+1,032
+10% +$69.4K 0.08% 73
2017
Q1
$672K Sell
10,306
-300
-3% -$18.9K 0.07% 72
2016
Q4
$664K Sell
10,606
-800
-7% -$48.8K 0.07% 72
2016
Q3
$719K Sell
11,406
-727
-6% -$47.1K 0.08% 71
2016
Q2
$751K Buy
12,133
+3,991
+49% +$243K 0.08% 69
2016
Q1
$465K Sell
8,142
-100
-1% -$5.57K 0.05% 78
2015
Q4
$488K Hold
8,242
0.06% 78
2015
Q3
$448K Sell
8,242
-50
-0.6% -$3.25K 0.06% 80
2015
Q2
$557K Sell
8,292
-191
-2% -$12.5K 0.06% 76
2015
Q1
$497K Sell
8,483
-7,600
-47% -$459K 0.06% 75
2014
Q4
$1.05M Hold
16,083
0.12% 62
2014
Q3
$929K Sell
16,083
-450
-3% -$25K 0.12% 62
2014
Q2
$933K Sell
16,533
-700
-4% -$36.7K 0.12% 62
2014
Q1
$886K Sell
17,233
-2,019
-10% -$102K 0.12% 61
2013
Q4
$1.02M Buy
19,252
+2,019
+12% +$99.2K 0.14% 58
2013
Q3
$771K Sell
17,233
-1,050
-6% -$46.5K 0.12% 62
2013
Q2
$756K Buy
+18,283
New +$800K 0.12% 62

Other funds holding ABBV

Farr Miller & Washington's ABBV Position: Q3 2021 in Review

Farr Miller & Washington increased its AbbVie (ABBV) stake by 0.44% in Q3 2021, buying an estimated $4.91K and bringing the position to 9,814 shares worth $1.06M. The position accounts for 0.07% of the portfolio, ranked #97.

Farr Miller & Washington first reported a position in ABBV in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.1M in Q2 2021. 2,654 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

  • Farr Miller & Washington held 9,814 shares of AbbVie worth $1.06M as of Q3 2021.
  • Farr Miller & Washington bought 43 AbbVie shares in Q3 2021, an estimated $4.91K.
  • AbbVie made up 0.07% of Farr Miller & Washington's portfolio in Q3 2021, its #97 holding.
  • Farr Miller & Washington first reported a position in AbbVie in Q2 2013 and has held it in 34 quarters since.
  • Farr Miller & Washington's AbbVie position peaked at $1.1M in Q2 2021.
  • 2,654 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on Farr Miller & Washington's 13F filing for Q3 2021, filed 15 Nov 2021.